Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting ovarian response to low-dose recombinant FSH in stimulated IUI cycles
NL-OMON43894Phase 2Active, not recruiting
- Sponsor
- Isala
- Start
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human follicle stimulating hormone and human chorionic gonadotropin in hypofertility, female infertility and male infertility, sponsored by Isala. Primary endpoint: Relationship between AMH and ovarian response. Started Dec 2012; status: active, not recruiting.
02
Drugs
recombinant human follicle stimulating hormonehuman chorionic gonadotropin
03
Conditions
hypofertilityfemale infertilitymale infertility
Beyond the preview
Go deeper on NL-OMON43894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43894.